Background: This article describes the differential diagnosis of conjunctival papillomas and reviews the treatment options with a focus on the new topical interferon alpha 2 beta therapy.

Case: A 45-year-old white man presented with a red right eye of approximately 6 months' duration. The lesion was suspicious and suggestive of malignancy; therefore, the patient was referred for consultation. The lesion was diagnosed as a conjunctival papilloma. The patient was placed on topical interferon alpha 2 beta eye drops, and within 2 weeks he experienced complete lesion regression.

Conclusion: Interferons, in particular interferon alpha-2b (IFN-alpha2beta), have recently been shown to be successful in treating conjunctival papillomas and conjunctival intraepithelial neoplasia (CIN). Previously, treatment was limited to observation for asymptomatic patients. Larger lesions in symptomatic patients were treated by surgical excision and cryotherapy. Additional treatment modalities included topical antimetabolite treatment with mitomycin-C and 5-fluorouracil. These treatments, although effective, had significant attendant postsurgical complications and toxic ocular adverse reactions. Interferons represent a new successful treatment modality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.optm.2006.10.017DOI Listing

Publication Analysis

Top Keywords

topical interferon
12
interferon alpha
12
alpha beta
12
conjunctival papilloma
8
conjunctival papillomas
8
conjunctival
5
treatment
5
topical
4
beta therapy
4
therapy management
4

Similar Publications

Periodontitis, a widespread inflammatory disease, is the major cause of tooth loss in adults. While mechanical periodontal therapy benefits the periodontal disease treatment, adjunctive periodontal therapy is also necessary. Topically applied anti-inflammatory agents have gained considerable attention in periodontitis therapy.

View Article and Find Full Text PDF

Introduction And Importance: Conjunctival squamous cell carcinoma (SCC) is the most advanced form of ocular surface squamous neoplasia (OSSN), with varying incidence rates influenced by factors such as age, UV exposure, and occupation. Early detection is crucial, but misdiagnosis is common, especially when SCC mimics benign conditions like pterygium.

Case Presentation: An 83-year-old Caucasian male farmer presented with a rapidly enlarging nasal limbal lesion, initially misdiagnosed as pterygium.

View Article and Find Full Text PDF

In vitro and in vivo evaluation of Ulva lactuca for wound healing.

PLoS One

January 2025

College of Nursing, Divisions of Basic Medicine, Tzu Chi University, Hualien, Taiwan.

Ulva lactuca (U. lactuca) is an important seaweed species. Some ingredients in this species are thought to accelerate wound healing.

View Article and Find Full Text PDF

Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear.

View Article and Find Full Text PDF

HDAC6 deacetylates TRIM56 to negatively regulate cGAS-STING-mediated type I interferon responses.

EMBO Rep

January 2025

Institute of Biomedicine, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Key Laboratory of Innovative Technology Research on Natural Products and Cosmetics Raw Materials, Jinan University, 510632, Guangzhou, China.

Histone deacetylase HDAC6 has been implicated in regulating antiviral innate immunity. However, its precise function in response to DNA virus infection remains elusive. Herein, we find that HDAC6 deficiency promotes the activation of cGAS-STING signaling and type I interferon (IFN) production, both in vitro and in vivo, resulting in a decrease in HSV-1 infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!